Alnylam Pharmace. buy Citigroup Inc.
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -20.31%. This prediction currently runs until 02.09.26. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -3.833% | -3.833% |
| iShares Core DAX® | -1.875% | 2.861% |
| iShares Nasdaq 100 | -2.177% | 0.048% |
| iShares Nikkei 225® | -0.867% | 6.987% |
| iShares S&P 500 | -1.253% | 1.248% |
Comments by Citigroup_Inc_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Citigroup_Inc_ for Alnylam Pharmace.
Alnylam Pharmace.
11.07.25
11.07.26
19.01.26
Alnylam Pharmace.
21.03.25
21.03.26
19.01.26
Alnylam Pharmace.
02.08.24
02.08.25
03.08.25
Alnylam Pharmace.
25.06.24
25.06.25
26.06.25
Alnylam Pharmace.
16.02.24
16.02.25
17.02.25

